サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1468096

抗毒素市場レポート：生物種、抗毒素タイプ、作用機序、エンドユーザー、地域別、2024～2032年

Anti-Venom Market Report by Species, Anti-venom Type, Mode of Action, End User, and Region 2024-2032

出版日
発行
IMARC
ページ情報
英文 135 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.33円
抗毒素市場レポート：生物種、抗毒素タイプ、作用機序、エンドユーザー、地域別、2024～2032年
出版日: 2024年04月08日
発行: IMARC
ページ情報: 英文 135 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の抗毒素市場規模は2023年に11億6,950万米ドルに達しました。今後、IMARC Groupは、市場が2024～2032年の間に6％の成長率（CAGR）を示し、2032年までに20億350万米ドルに達すると予測しています。ヘビに咬まれたりサソリに刺されたりする事例の増加、有利な政府イニシアチブの実施、業界における継続的な技術革新は、市場を牽引する主要要因のいくつかです。

抗毒素は、毒血清としても知られ、ヘビ、クモ、サソリ、クラゲやイモガイなどの特定の海洋生物を含む動物による毒咬傷や刺傷の影響を治療するために使用される薬の一種を指します。加害動物から毒を抽出し、免疫系が抗体を産生するウマ、ヒツジ、ヤギなどの動物に少量の毒を注射することで得られます。抗毒素は毒素を中和し、毒の影響を打ち消して、呼吸不全や臓器障害といった生命を脅かす合併症を引き起こすのを防ぎます。抗ベノムは、病歴、試験、地理的・臨床的・病理学的要因に応じて、毒に刺されたり噛まれたりした際の治療に世界中で広く採用されています。

抗毒素市場の動向：

特に農村部や熱帯地域、農業従事者や狩猟者の間で、世界中で毒に咬まれたり刺されたりするケースが増加していることが、市場成長を促進する主要因の1つとなっています。これに加えて、ヘビ咬傷予防の重要性に対する消費者の意識の高まりと、手頃な価格で簡単に製品を入手できることが、市場に有利な展望を生み出しています。さらに、教育や訓練プログラムなど、ヘビ咬傷に対抗するための数多くの政府イニシアチブの実施や、新しい抗毒素の研究開発（R&D）活動への集中的な投資が、市場の成長に寄与しています。これに加えて、動物性タンパク質に対する需要の高まりに伴い、ヘビに咬まれる危険性のある家畜やその他の動物の数が増加しており、これが市場に有益な成長機会をもたらしています。これと同時に、島、砂漠、ジャングル、サファリなどのエキゾチックな目的地を旅行したり探検したりする人気の高まりも、観光客をヘビ咬傷やその他の毒動物との遭遇の危険にさらしており、もう一つの重要な成長促進要因として作用しています。さらに、バイオテクノロジーや医療産業における数々の技術的進歩や、より効果的で効率的な抗毒素製品の製造を可能にする製造技術の革新的改良が続いていることも、市場成長にプラスの影響を与えています。これとは別に、咬まれた部位、尿、血漿、血液、またはその他の組織や体液から採取したサンプルからヘビ毒を検出・同定するための迅速酵素免疫測定法を利用した様々な迅速ヘビ毒検出キットの発売が、市場を前進させています。

本レポートで扱う主要質問

  • 2023年の世界の抗毒素市場の規模は？
  • 2024～2032年の間に予想される世界の抗毒素市場の成長率は？
  • COVID-19が世界の抗毒素市場に与えた影響は？
  • 世界の抗毒素市場を牽引する主要因は？
  • 生物種別の世界の抗毒素市場の内訳は？
  • 抗毒素タイプ別の抗毒素の世界市場の内訳は？
  • 抗毒素の作用機序別の世界市場の内訳は？
  • エンドユーザー別の抗毒素の世界市場内訳は？
  • 抗毒素の世界市場における主要地域は？
  • 抗毒素の世界市場における主要参入企業は？

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査目的
  • 利害関係者
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要産業動向

第5章 抗ベノムの世界市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第6章 市場内訳：生物種別

  • ヘビ
  • サソリ
  • クモ
  • その他

第7章 市場内訳：抗毒素タイプ別

  • 多価抗毒素
  • 一価抗毒素

第8章 市場内訳：作用機序別

  • 細胞毒性
  • 神経毒性
  • 血毒性
  • 心臓毒性
  • 筋毒性
  • その他

第9章 市場内訳：エンドユーザー別

  • 病院
  • クリニック
  • 外来手術センター

第10章 市場内訳：地域別

  • 北米
    • 米国
    • カナダ
  • アジア太平洋
    • 中国
    • 日本
    • インド
    • 韓国
    • オーストラリア
    • インドネシア
    • その他
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • ロシア
    • その他
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • その他
  • 中東・アフリカ
    • 市場動向
    • 市場内訳：国別
    • 市場予測

第11章 SWOT分析

  • 概要
  • 強み
  • 弱み
  • 機会
  • 脅威

第12章 バリューチェーン分析

第13章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第14章 価格分析

第15章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • Bharat Serums and Vaccines Limited（BSV）
    • Boehringer Ingelheim International GmbH
    • Boston Scientific Corporation
    • CSL Limited
    • Haffkine Bio-Pharmaceutical Corporation Limited
    • Incepta Pharmaceuticals Limited
    • Merck & Co. Inc.
    • Merck KGaA
    • MicroPharm Limited
    • Pfizer Inc.
    • Rare Disease Therapeutics Inc.
図表

List of Figures

  • Figure 1: Global: Anti-venom Market: Major Drivers and Challenges
  • Figure 2: Global: Anti-venom Market: Sales Value (in Million US$), 2018-2023
  • Figure 3: Global: Anti-venom Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 4: Global: Anti-venom Market: Breakup by Species (in %), 2023
  • Figure 5: Global: Anti-venom Market: Breakup by Anti-venom Type (in %), 2023
  • Figure 6: Global: Anti-venom Market: Breakup by Mode of Action (in %), 2023
  • Figure 7: Global: Anti-venom Market: Breakup by End User (in %), 2023
  • Figure 8: Global: Anti-venom Market: Breakup by Region (in %), 2023
  • Figure 9: Global: Anti-venom (Snake) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 10: Global: Anti-venom (Snake) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 11: Global: Anti-venom (Scorpion) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 12: Global: Anti-venom (Scorpion) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 13: Global: Anti-venom (Spider) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 14: Global: Anti-venom (Spider) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 15: Global: Anti-venom (Other Species) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 16: Global: Anti-venom (Other Species) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 17: Global: Anti-venom (Polyvalent Anti-venom) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 18: Global: Anti-venom (Polyvalent Anti-venom) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 19: Global: Anti-venom (Monovalent Anti-venom) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 20: Global: Anti-venom (Monovalent Anti-venom) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 21: Global: Anti-venom (Cytotoxic) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 22: Global: Anti-venom (Cytotoxic) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 23: Global: Anti-venom (Neurotoxic) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 24: Global: Anti-venom (Neurotoxic) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 25: Global: Anti-venom (Haemotoxic) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 26: Global: Anti-venom (Haemotoxic) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 27: Global: Anti-venom (Cardiotoxic) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 28: Global: Anti-venom (Cardiotoxic) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 29: Global: Anti-venom (Myotoxic) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 30: Global: Anti-venom (Myotoxic) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 31: Global: Anti-venom (Other Mode of Actions) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 32: Global: Anti-venom (Other Mode of Actions) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 33: Global: Anti-venom (Hospitals) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 34: Global: Anti-venom (Hospitals) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 35: Global: Anti-venom (Clinics) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 36: Global: Anti-venom (Clinics) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 37: Global: Anti-venom (Ambulatory Surgical Centers) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 38: Global: Anti-venom (Ambulatory Surgical Centers) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 39: North America: Anti-venom Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 40: North America: Anti-venom Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 41: United States: Anti-venom Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 42: United States: Anti-venom Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 43: Canada: Anti-venom Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 44: Canada: Anti-venom Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 45: Asia-Pacific: Anti-venom Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 46: Asia-Pacific: Anti-venom Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 47: China: Anti-venom Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 48: China: Anti-venom Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 49: Japan: Anti-venom Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 50: Japan: Anti-venom Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 51: India: Anti-venom Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 52: India: Anti-venom Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 53: South Korea: Anti-venom Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 54: South Korea: Anti-venom Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 55: Australia: Anti-venom Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 56: Australia: Anti-venom Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 57: Indonesia: Anti-venom Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 58: Indonesia: Anti-venom Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 59: Others: Anti-venom Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 60: Others: Anti-venom Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 61: Europe: Anti-venom Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 62: Europe: Anti-venom Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 63: Germany: Anti-venom Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 64: Germany: Anti-venom Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 65: France: Anti-venom Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 66: France: Anti-venom Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 67: United Kingdom: Anti-venom Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 68: United Kingdom: Anti-venom Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 69: Italy: Anti-venom Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 70: Italy: Anti-venom Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 71: Spain: Anti-venom Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 72: Spain: Anti-venom Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 73: Russia: Anti-venom Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 74: Russia: Anti-venom Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 75: Others: Anti-venom Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 76: Others: Anti-venom Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 77: Latin America: Anti-venom Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 78: Latin America: Anti-venom Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 79: Brazil: Anti-venom Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 80: Brazil: Anti-venom Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 81: Mexico: Anti-venom Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 82: Mexico: Anti-venom Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 83: Others: Anti-venom Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 84: Others: Anti-venom Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 85: Middle East and Africa: Anti-venom Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 86: Middle East and Africa: Anti-venom Market: Breakup by Country (in %), 2023
  • Figure 87: Middle East and Africa: Anti-venom Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 88: Global: Anti-venom Industry: SWOT Analysis
  • Figure 89: Global: Anti-venom Industry: Value Chain Analysis
  • Figure 90: Global: Anti-venom Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Anti-venom Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Anti-venom Market Forecast: Breakup by Species (in Million US$), 2024-2032
  • Table 3: Global: Anti-venom Market Forecast: Breakup by Anti-venom Type (in Million US$), 2024-2032
  • Table 4: Global: Anti-venom Market Forecast: Breakup by Mode of Action (in Million US$), 2024-2032
  • Table 5: Global: Anti-venom Market Forecast: Breakup by End User (in Million US$), 2024-2032
  • Table 6: Global: Anti-venom Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 7: Global: Anti-venom Market: Competitive Structure
  • Table 8: Global: Anti-venom Market: Key Players
目次
Product Code: SR112024A5147

The global anti-venom market size reached US$ 1,169.5 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 2,003.5 Million by 2032, exhibiting a growth rate (CAGR) of 6% during 2024-2032. The rising incidences of snake bites and scorpion stings, the implementation of favorable government initiatives, and ongoing innovations in the industry represent some of the key factors driving the market.

Anti-venom, also known as venom antiserum, refers to a type of medication used to treat the effects of venomous bites or stings from animals, including snakes, spiders, scorpions, and certain marine creatures such as jellyfish or cone snails. It is obtained by extracting venom from the offending animal and then injecting small amounts of the venom into animals, such as horses, sheep, or goats, whose immune systems produce antibodies that are harvested and purified to create anti-venom. Anti-venom neutralizes the toxins and counteracts the effects of the venom, preventing them from causing life-threatening complications such as respiratory failure or organ damage. It is extensively adopted across the globe in treating venomous bites and stings, depending on their history, examination, and geographic, clinical, and pathologic factors.

Anti-Venom Market Trends:

The rise in cases of venomous bites and stings across the world, particularly in rural and tropical regions and among agricultural workers and hunters, represents one of the prime factors driving the market growth. Besides this, the escalating consumer awareness of the importance of snake bite prevention and easy product availability at an affordable price is creating a favorable outlook for the market. Moreover, the implementation of numerous government initiatives to combat snake bites, such as education and training programs, and intensive investments in research and development (R&D) activities of new anti-venom products are contributing to the market growth. In addition to this, with the rising demand for animal-based protein, there is an increase in the number of livestock and other animals at risk of snake bites, which, in turn, is presenting remunerative growth opportunities for the market. Concurrent with this, the rising popularity of traveling and exploring exotic destinations, such as islands, deserts, jungles, and safaris, that puts tourists at risk of snake bites and other venomous animal encounters is acting as another significant growth-inducing factor. Furthermore, numerous technological advancements in the biotechnology and healthcare industries and ongoing innovative improvements in manufacturing technology, allowing for the production of more effective and efficient anti-venom products, are positively impacting the market growth. Apart from this, the launch of various rapid snake venom detection kits, which utilize a rapid enzyme immunoassay to detect and identify snake venom through samples taken from bite sites, urine, plasma, blood, or other tissues and body fluids, is propelling the market forward.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global anti-venom market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on species, anti-venom type, mode of action and end user.

Species Insights:

Snake

Scorpion

Spider

Others

The report has provided a detailed breakup and analysis of the anti-venom market based on the species. This includes snake, scorpion, spider, and others. According to the report, snake represented the largest segment.

Anti-venom Type Insights:

Polyvalent Anti-venom

Monovalent Anti-venom

A detailed breakup and analysis of the anti-venom market based on the anti-venom type has also been provided in the report. This includes polyvalent and monovalent anti-venom. According to the report, polyvalent anti-venom accounted for the largest market share.

Mode of Action Insights:

Cytotoxic

Neurotoxic

Haemotoxic

Cardiotoxic

Myotoxic

Others

The report has provided a detailed breakup and analysis of the anti-venom market based on the mode of action. This includes cytotoxic, neurotoxic, haemotoxic, cardiotoxic, myotoxic, and others. According to the report, neurotoxic represented the largest segment.

End User Insights:

Hospitals

Clinics

Ambulatory Surgical Centers

A detailed breakup and analysis of the anti-venom market based on the end user has also been provided in the report. This includes hospitals, clinics, and ambulatory surgical centers. According to the report, hospitals accounted for the largest market share.

Regional Insights:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for anti-venom. Some of the factors driving the North America anti-venom market included the increasing incidence of snake bites, the introduction of numerous favorable government initiatives, and the thriving travel and tourism sector.

Competitive Landscape:

The report has also provided a comprehensive analysis of the competitive landscape in the global anti-venom market. Competitive analysis such as market structure, market share by key players, player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided. Some of the companies covered include Bharat Serums and Vaccines Limited (BSV), Boehringer Ingelheim International GmbH, Boston Scientific Corporation, CSL Limited, Haffkine Bio-Pharmaceutical Corporation Limited, Incepta Pharmaceuticals Limited, Merck & Co. Inc., Merck KGaA, MicroPharm Limited, Pfizer Inc., and Rare Disease Therapeutics Inc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Questions Answered in This Report

  • 1. What was the size of the global anti-venom market in 2023?
  • 2. What is the expected growth rate of the global anti-venom market during 2024-2032?
  • 3. What has been the impact of COVID-19 on the global anti-venom market?
  • 4. What are the key factors driving the global anti-venom market?
  • 5. What is the breakup of the global anti-venom market based on the species?
  • 6. What is the breakup of the global anti-venom market based on the anti-venom type?
  • 7. What is the breakup of the global anti-venom market based on the mode of action?
  • 8. What is the breakup of the global anti-venom market based on the end user?
  • 9. What are the key regions in the global anti-venom market?
  • 10. Who are the key players/companies in the global anti-venom market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Anti-venom Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Species

  • 6.1 Snake
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Scorpion
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Spider
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Others
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast

7 Market Breakup by Anti-venom Type

  • 7.1 Polyvalent Anti-venom
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Monovalent Anti-venom
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by Mode of Action

  • 8.1 Cytotoxic
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Neurotoxic
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Haemotoxic
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Cardiotoxic
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast
  • 8.5 Myotoxic
    • 8.5.1 Market Trends
    • 8.5.2 Market Forecast
  • 8.6 Others
    • 8.6.1 Market Trends
    • 8.6.2 Market Forecast

9 Market Breakup by End User

  • 9.1 Hospitals
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Clinics
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Ambulatory Surgical Centers
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia-Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Bharat Serums and Vaccines Limited (BSV)
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
    • 15.3.2 Boehringer Ingelheim International GmbH
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
    • 15.3.3 Boston Scientific Corporation
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
      • 15.3.3.3 Financials
      • 15.3.3.4 SWOT Analysis
    • 15.3.4 CSL Limited
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 Financials
      • 15.3.4.4 SWOT Analysis
    • 15.3.5 Haffkine Bio-Pharmaceutical Corporation Limited
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
    • 15.3.6 Incepta Pharmaceuticals Limited
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
    • 15.3.7 Merck & Co. Inc.
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
      • 15.3.7.3 Financials
      • 15.3.7.4 SWOT Analysis
    • 15.3.8 Merck KGaA
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
      • 15.3.8.3 Financials
      • 15.3.8.4 SWOT Analysis
    • 15.3.9 MicroPharm Limited
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
    • 15.3.10 Pfizer Inc.
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio
      • 15.3.10.3 Financials
      • 15.3.10.4 SWOT Analysis
    • 15.3.11 Rare Disease Therapeutics Inc.
      • 15.3.11.1 Company Overview
      • 15.3.11.2 Product Portfolio